Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03910244 · ClinicalTrials.gov registry record · Phase 2
Pomalidomide for the Treatment of Bleeding in HHT
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT03910244 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 145 participants.
The verdict
NCT03910244, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or blood transfusions. A total of 159 patients will be randomized 2:1 to treatment with oral pomalidomide or matching placebo for 24 weeks. Mean change from baseline to 24 weeks in the Epistaxis Severity Score (ESS) will be compared between treatment groups to determine pomalidomide efficacy.
Interventions
- DRUG Placebo oral capsule
- DRUG Pomalidomide Oral Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03910244
The ClinicalTrials.gov registry entry for NCT03910244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03910244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03910244 about?
NCT03910244 is a clinical study titled "Pomalidomide for the Treatment of Bleeding in HHT". This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or blood transfusions. A total of 159 patients will be randomized 2:1 to tr...
What is the current status of trial NCT03910244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2019-10-17. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT03910244?
The interventions under investigation include: Placebo oral capsule (DRUG), Pomalidomide Oral Product (DRUG).
Who is sponsoring clinical trial NCT03910244?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.